Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3029604 | 0.79 | MAP3K14 (0.49) | MAP3K14PIK3CGSCN10APIK3CAMTOR | |
| SCHEMBL31423373 | 0.78 | POLB (0.41) | MAP3K14POLBPIK3CGCHEK1CYP1A2 | |
| SCHEMBL17754846 | 0.76 | TGFBR1 (0.43) | MAP3K14POLBCYP1A2CYP2C9TGFBR1 | |
| SCHEMBL3020269 | 0.76 | POLB (0.51) | MAP3K14POLBALDH1A1 | |
| SCHEMBL13676388 | 0.76 | CYP1A2 (0.53) | MAP3K14POLBALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL30218126 | 0.76 | MAP3K14 (0.33) | MAP3K14POLBCHEK1CYP1A2CYP2C9 | |
| SCHEMBL3026036 | 0.76 | MAP3K14 (0.33) | MAP3K14POLBSCN10APIK3CAMTOR | |
| Bromide SCHEMBL30431359 | 0.74 | TGFBR1 (0.42) | MAP3K14POLBCYP1A2CYP2C9TGFBR1 | |
| Bromide SCHEMBL3016136 | 0.74 | POLB (0.50) | MAP3K14POLBALDH1A1 | |
| SCHEMBL27399244 | 0.73 | IRAK4 (0.42) | SCN10ATGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695246-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| CN-119707925-A | Compounds as KIF18A inhibitors and uses thereof | 南京圣和药物研发有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240368168-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND APPLICATION THEREOF | ARTIVILA BIOPHARMA (CN) | 2024-11-07 | — | — | US | disclosed |
| WO-2024213653-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-10-17 | — | — | WO | disclosed |
| WO-2023025244-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND APPLICATION THEREOF | 科辉智药生物科技(深圳)有限公司 | 2023-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368168-A1 | SARM1 ENZYME ACTIVITY INHIBITOR AND APPLICATION THEREOF | SARM1, BACE1, SARNP | MAP3K14 2060/4885POLB 1309/4885PIK3CG 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.